Τετάρτη 8 Φεβρουαρίου 2017

Serum albumin predicts survival in patients with hilar cholangiocarcinoma

<span class="paragraphSection"><strong>Background and aims:</strong> Hilar cholangiocarcinoma is a devastating malignancy with incidence varying by geography and other risk factors. Rapid progression of disease and delays in diagnosis restrict the number of patients eligible for curative therapy. The objective of this study was to determine prognostic factors of overall survival in all patients presenting with hilar cholangiocarcinoma.<strong>Methods:</strong> All adult patients with histologically confirmed hilar cholangiocarcinoma from 2003 to 2013 were evaluated for predictors of survival using demographic factors<span style="font-style:italic;">,</span> laboratory data<span style="font-style:italic;">,</span> symptoms and radiological characteristics at presentation.<strong>Results:</strong> A total of 116 patients were identified to have pathological diagnosis of hilar cholangiocarcinoma and were included in the analysis. Patients with a serum albumin level >3.0 g/dL (<span style="font-style:italic;">P < </span>0.01)<span style="font-style:italic;">,</span> cancer antigen 19‐9 ≤200 U/mL (<span style="font-style:italic;">P = </span>0.03)<span style="font-style:italic;">,</span> carcinoembryonic antigen ≤10 ìg/L (<span style="font-style:italic;">P < </span>0.01) or patients without a history of cirrhosis (<span style="font-style:italic;">P < </span>0.01) or diabetes (<span style="font-style:italic;">P = </span>0.02) were associated with a greater length of overall survival. A serum albumin level >3.0 g/dL was identified as an independent predictor of overall survival (hazard ratio 0.31; 95% confidence interval 0.14–0.70) with a survival benefit of 44 weeks.<strong>Conclusion:</strong> This study was the largest analysis to date of prognostic factors in patients with hilar cholangiocarcinoma. A serum albumin level >3.0 g/dL conferred an independent survival advantage with a significantly greater length of survival.</span>

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2k5g06Y
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις